Exploratory study of blood biomarkers to predict the therapeutic effect of nintedanib in idiopathic pulmonary fibrosis (IPF)
Not Applicable
- Conditions
- idiopathic pulmonary fibrosis (IPF)
- Registration Number
- JPRN-UMIN000036457
- Lead Sponsor
- Chiba University Hospital, Respiratory medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients who can not get consent 2 patients whom the doctor in charge deems inappropriate 3 Patients with acute exacerbation at time 4 Patients with malignancy 5 Patients scheduled for surgery within 6 months 6 Patients with severe liver disorder (Child-Pugh B or more) 7 Patients whose prognosis is predicted to be less than 6 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method